{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T01:57:55Z","timestamp":1785031075715,"version":"3.55.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","award":["70114086"],"award-info":[{"award-number":["70114086"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["WU977\/2-1"],"award-info":[{"award-number":["WU977\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.drup.2025.101242","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T15:22:29Z","timestamp":1743434549000},"page":"101242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A quiescence-like\/TGF-\u03b21-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML"],"prefix":"10.1016","volume":"81","author":[{"given":"Elahe","family":"Rahimian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Koochak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Traikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2848-6949","authenticated-orcid":false,"given":"Michael","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Brilloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2431-7654","authenticated-orcid":false,"given":"Vida","family":"Kufrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"K\u00fcchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mirtschink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Baretton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3377-1704","authenticated-orcid":false,"given":"Evelin","family":"Schr\u00f6ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis M.","family":"Schewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia R.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Glimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Bill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Wurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2025.101242_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2025.101242_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drup.2025.101242_bib3","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.3390\/curroncol29090491","article-title":"Management of acute myeloid leukemia: a review for general practitioners in oncology","volume":"29","author":"Stubbins","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.drup.2025.101242_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00277-010-1118-7","article-title":"Leukemia stem cells","volume":"90","author":"Testa","year":"2011","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.drup.2025.101242_bib5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","article-title":"Biology and relevance of human acute myeloid leukemia stem cells","volume":"129","author":"Thomas","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101242_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.drup.2025.101242_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drup.2025.101242_bib8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/0008-5472.CAN-18-2932","article-title":"Single-cell gene expression analyses reveal distinct self-renewing and proliferating subsets in the leukemia stem cell compartment in acute myeloid leukemia","volume":"80","author":"Sachs","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2025.101242_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-13-7342-8_1","article-title":"Signaling pathways in leukemic stem cells","volume":"1143","author":"Gurska","year":"2019","journal-title":"Adv. Exp. Med Biol."},{"key":"10.1016\/j.drup.2025.101242_bib10","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.4161\/cc.29156","article-title":"Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness","volume":"13","author":"Yano","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.drup.2025.101242_bib11","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1158\/0008-5472.CAN-21-1407","article-title":"Translating the Science of Cancer Dormancy to the Clinic","volume":"81","author":"J.A.","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2025.101242_bib12","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/ncb2861","article-title":"TGF-\u03b22 dictates disseminated tumour cell fate in target organs through TGF-\u03b2-RIII and p38\u03b1\/\u03b2 signalling","volume":"15","author":"Bragado","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.drup.2025.101242_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41467-020-20664-5","article-title":"Dll1+\u2009quiescent tumor stem cells drive chemoresistance in breast cancer through NF-\u03baB survival pathway","volume":"12","author":"Kumar","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2025.101242_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/7367854","article-title":"SETD4 confers cancer stem cell chemoresistance in nonsmall cell lung cancer patients via the epigenetic regulation of cellular quiescence","volume":"2023","author":"Wang","year":"2023","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.drup.2025.101242_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131486","article-title":"NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer","volume":"5","author":"Cole","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.drup.2025.101242_bib16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41467-020-14590-9","article-title":"FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML","volume":"11","author":"Sheng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2025.101242_bib17","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/blood-2022-158884","article-title":"The role of quiescence in acute myeloid leukemia growth","volume":"140","author":"Restelli","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101242_bib18","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2025.101242_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-4939-7371-2_3","article-title":"Flow cytometric detection of g0 in live cells by hoechst 33342 and pyronin Y staining","volume":"1686","author":"Eddaoudi","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.drup.2025.101242_bib20","article-title":"Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity","volume":"4","author":"Wurm","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.drup.2025.101242_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet J."},{"key":"10.1016\/j.drup.2025.101242_bib22","doi-asserted-by":"crossref","unstructured":"McKinney W. Data Structures for Statistical Computing in Python. Austin, Texas; 2010 [cited 2024 Aug 17]. page 56\u201361. Available from: \u3008https:\/\/conference.scipy.org\/proceedings\/scipy2010\/mckinney.html\u3009.","DOI":"10.25080\/Majora-92bf1922-00a"},{"key":"10.1016\/j.drup.2025.101242_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: A 2D graphics environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Comput. Sci. Eng."},{"key":"10.1016\/j.drup.2025.101242_bib24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.19760","article-title":"Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation","volume":"5","author":"Horlbeck","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.drup.2025.101242_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku749","article-title":"Multiplex CRISPR\/Cas9-based genome engineering from a single lentiviral vector","volume":"42","author":"Kabadi","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2025.101242_bib26","unstructured":"ByteDance AML AI4Science Team, Chen X., Zhang Y., Lu C., Ma W., Guan J., et al. Protenix - Advancing Structure Prediction Through a Comprehensive AlphaFold3 Reproduction [Internet]. 2025 [cited 2025 Feb 22]. Available from: \u3008http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.01.08.631967\u3009."},{"key":"10.1016\/j.drup.2025.101242_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drup.2025.101242_bib28","doi-asserted-by":"crossref","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drup.2025.101242_bib29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41594-019-0245-7","article-title":"Structures of human ENT1 in complex with adenosine reuptake inhibitors","volume":"26","author":"Wright","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.drup.2025.101242_bib30","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2025.101242_bib31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2025.101242_bib32","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1634\/stemcells.2007-0250","article-title":"Transcriptional analysis of quiescent and proliferating CD34+\u2009human hemopoietic cells from normal and chronic myeloid leukemia sources","volume":"25","author":"Graham","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.drup.2025.101242_bib33","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2025.101242_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat. Genet"},{"key":"10.1016\/j.drup.2025.101242_bib35","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3390\/ijms17111849","article-title":"The bromodomain and extra-terminal domain (BET) family: functional anatomy of BET paralogous proteins","volume":"17","author":"Taniguchi","year":"2016","journal-title":"IJMS"},{"key":"10.1016\/j.drup.2025.101242_bib36","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-21-0029","article-title":"Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2025.101242_bib37","doi-asserted-by":"crossref","first-page":"17698","DOI":"10.18632\/oncotarget.4131","article-title":"BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells","volume":"6","author":"Coud\u00e9","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2025.101242_bib38","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-23-2823","article-title":"Clinical activity of TGF-\u03b2 inhibitor vactosertib in combination with imatinib in desmoid tumors: a multicenter phase Ib\/II study","volume":"30","author":"Ahn","year":"2024","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2025.101242_bib39","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1200\/JCO.2021.39.15_suppl.3573","article-title":"Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer","volume":"39","author":"Kim","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.drup.2025.101242_bib40","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1158\/1078-0432.CCR-19-1338","article-title":"Phase II study of the ALK5 inhibitor galunisertib in very low-, low-, and intermediate-risk myelodysplastic syndromes","volume":"25","author":"Santini","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2025.101242_bib41","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1158\/1535-7163.MCT-13-0903","article-title":"EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis","volume":"13","author":"Son","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.drup.2025.101242_bib42","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cac2.12589","article-title":"Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity","volume":"44","author":"Choi","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.drup.2025.101242_bib43","first-page":"3112163","article-title":"Vactosertib, a novel TGF-\u03b21 type I receptor kinase inhibitor, improves T-cell fitness: a single-arm, phase 1b trial in relapsed\/refractory multiple myeloma","author":"Malek","year":"2023","journal-title":"Res Sq."},{"key":"10.1016\/j.drup.2025.101242_bib44","doi-asserted-by":"crossref","first-page":"a022061","DOI":"10.1101\/cshperspect.a022061","article-title":"TGF-\u03b2 signaling from receptors to smads","volume":"8","author":"Hata","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.drup.2025.101242_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bcp.2012.03.022","article-title":"Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells","volume":"84","author":"Amsailale","year":"2012","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.drup.2025.101242_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15257770.2016.1210805","article-title":"Equilibrative nucleoside transporters-A review","volume":"36","author":"Boswell-Casteel","year":"2017","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.drup.2025.101242_bib47","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood.2020007281","article-title":"The equilibrative nucleoside transporter ENT1 is critical for nucleotide homeostasis and optimal erythropoiesis","volume":"137","author":"Mikdar","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101242_bib48","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/cpt.2984","article-title":"Addressing the clinical importance of equilibrative nucleoside transporters in drug discovery and development","volume":"114","author":"Hau","year":"2023","journal-title":"Clin. Pharma Ther."},{"key":"10.1016\/j.drup.2025.101242_bib49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s13318-021-00703-2","article-title":"Differential inhibition of equilibrative nucleoside transporter 1 (ENT1) activity by tyrosine kinase inhibitors","volume":"46","author":"Jouan","year":"2021","journal-title":"Eur. J. Drug Metab. Pharm."},{"key":"10.1016\/j.drup.2025.101242_bib50","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101242_bib51","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1158\/1078-0432.CCR-20-4271","article-title":"FDA approval summary: gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation","volume":"27","author":"Pulte","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2025.101242_bib52","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-19-0365","article-title":"FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2025.101242_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5045\/br.2023.2023136","article-title":"Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm","volume":"58","author":"Kim","year":"2023","journal-title":"Blood Res."},{"key":"10.1016\/j.drup.2025.101242_bib54","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.stem.2017.10.001","article-title":"TGF-\u03b2-induced quiescence mediates chemoresistance of tumor-propagating cells in squamous cell carcinoma","volume":"21","author":"Brown","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drup.2025.101242_bib55","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cell.2015.01.043","article-title":"TGF-\u03b2 promotes heterogeneity and drug resistance in squamous cell carcinoma","volume":"160","author":"Oshimori","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.drup.2025.101242_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay1813","article-title":"Tumor-initiating cells establish an IL-33-TGF-\u03b2 niche signaling loop to promote cancer progression","volume":"369","author":"Taniguchi","year":"2020","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.drup.2025.101242_bib57","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"Li","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.drup.2025.101242_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.111027","article-title":"The roles and mechanisms of TGFB1 in acute myeloid leukemia chemoresistance","volume":"116","author":"Liang","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.drup.2025.101242_bib59","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.3324\/haematol.2020.271627","article-title":"Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the MLL gene","volume":"106","author":"Bill","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2025.101242_bib60","first-page":"2709282","article-title":"Oral TGF-\u03b2R1 inhibitor Vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity","author":"Choi","year":"2023","journal-title":"Res Sq."},{"key":"10.1016\/j.drup.2025.101242_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114716","article-title":"Vactosertib, TGF-\u03b2 receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer","volume":"162","author":"Lee","year":"2023","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.drup.2025.101242_bib62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41419-023-05630-5","article-title":"Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-\u03b2 signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors","volume":"14","author":"Hong","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2025.101242_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.534","article-title":"Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice","volume":"7","author":"Anderson","year":"2019","journal-title":"Pharm. Res. Perspect."},{"key":"10.1016\/j.drup.2025.101242_bib64","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.febslet.2008.12.041","article-title":"Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells","volume":"583","author":"Zimmerman","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.drup.2025.101242_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037203","article-title":"Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis","volume":"7","author":"Macanas-Pirard","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2025.101242_bib66","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1158\/0008-5472.CAN-16-2548","article-title":"OCTN1 Is a high-affinity carrier of nucleoside analogues","volume":"77","author":"Drenberg","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2025.101242_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115930","article-title":"ABC transporters are predictors of treatment failure in acute myeloid leukaemia","volume":"170","author":"Cerovska","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2025.101242_bib68","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1158\/1078-0432.CCR-08-0442","article-title":"Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival","volume":"15","author":"Guo","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2025.101242_bib69","article-title":"Selective dysregulation of ABC transporters in methotrexate-resistant leukemia T-cells can confer cross-resistance to cytarabine, vincristine and dexamethasone, but not doxorubicin","volume":"69","author":"Aberuyi","year":"2021","journal-title":"Curr. Res. Transl. Med."},{"key":"10.1016\/j.drup.2025.101242_bib70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/cts.12366","article-title":"ABCC4 is a determinant of cytarabine-induced cytotoxicity and myelosuppression","volume":"9","author":"Drenberg","year":"2016","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.drup.2025.101242_bib71","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drup.2012.01.005","article-title":"Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance","volume":"15","author":"Shukla","year":"2012","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2025.101242_bib72","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2025.101242_bib73","article-title":"FRAX486, a PAK inhibitor, overcomes ABCB1-mediated multidrug resistance in breast cancer cells","volume":"57","author":"Zhang","year":"2024","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.drup.2025.101242_bib74","doi-asserted-by":"crossref","first-page":"18809","DOI":"10.1074\/jbc.M116.741074","article-title":"Selective inhibition of human equilibrative and concentrative nucleoside transporters by BCR-ABL kinase inhibitors: identification of key hENT1 amino acid residues for interaction with BCR-ABL kinase inhibitors","volume":"291","author":"Damaraju","year":"2016","journal-title":"J. Biol. Chem."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:24:28Z","timestamp":1778804668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764625000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":74,"alternative-id":["S1368764625000421"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2025.101242","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A quiescence-like\/TGF-\u03b21-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2025.101242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101242"}}